The promise of personalized medicine–or clinical intervention tailored to the individual patient–has grown closer to reality in recent years, particularly as researchers understand more about genetics and the role that variances, or mutations, in an individual’s DNA can play in diseases and response to drugs. In particular, “pharmacogenetics” analyzes patients’ genomes for variations that are known to impact drug safety and efficacy.

While a few expensive clinical assays have been available in recent years testing for a narrow scope of known genetic mutations, RPRD Diagnostics has taken this testing a step further, developing cost-effective testing services that survey literally thousands of clinically actionable genetic variants. Knowing these variants, which impact drug safety and efficacy, enables clinicians to make better informed decisions about the safest drug treatment for their patients in a way that can improve patient outcomes, reduce the risk of negative drug reactions and lower overall costs.

RPRD will be working with St. Jude Children’s Research Hospital to implement a PG4KDS program to comprehensively screen every patient prior to treatment. These results will be entered into the patient’s electronic medical record, and thus be available throughout the patient’s lifetime to aid in clinical care. This pharmacogenetics information supports clinicians in making better decision when choosing and dosing a drug, not only now but also as the patient ages. St. Jude is truly a leader in preemptive pharmacogenetics testing and setting up their young patients for a lifetime of better care.